Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR | Market Cap | 959.71B |
| Revenue (ttm) | 311.31B |
| Net Income (ttm) | 53.68B |
| Shares Out | n/a |
| EPS (ttm) | 64.35 |
| PE Ratio | 17.88 |
| Forward PE | n/a |
| Dividend | 8.00 (0.69%) |
| Ex-Dividend Date | n/a |
| Volume | 6,828,590 |
| Average Volume | 2,323,066 |
| Open | 1,170.70 |
| Previous Close | 1,170.95 |
| Day's Range | 1,145.25 - 1,170.75 |
| 52-Week Range | 1,120.00 - 1,421.49 |
| Beta | 0.37 |
| RSI | 29.40 |
| Earnings Date | May 7, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Nifty 50 top losers today on February 19: Dr. Reddy’s Laboratories, TCS, Infosys and Hindustan Unilever
The Indian stock market witnessed a volatile trading session on February 19, 2024, with the benchmark indices ending marginally lower. The BSE Sensex closed at 75,939.18, down by 28.21 points (-0.04%)...
Dr Reddy’s inks exclusive deal for cancer drug in US, EU
Hyderabad: Dr Reddy's Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma giant Dr Reddy's Laboratories Ltd, entered into a l.
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple myeloma therapy Darzalex. Read more here.
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr...
Dr. Reddy’s signs $131.6 million deal with Henlius to commercialize multiple myeloma biosimilar in US and Europe
Dr. Reddy’s Laboratories Limited has entered a strategic collaboration with Shanghai Henlius Biotech, Inc. for the development and commercialization of HLX15, a biosimilar to Darzalex® and Darzalex Fa...
Nifty 50 top gainers today on February 6: Cipla, ITC Hotels, Dr. Reddy’s Laboratories, HDFC Life and more
The Indian equity markets faced a downward trend on February 6, with major indices ending in the red. The Nifty 50 concluded the session at 23,603.35, experiencing a decline of 138.05 points, or 0.39%...
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased revenue. See why RDY stock is a Buy.
Dr. Reddy's Laboratories Limited 2025 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Dr. Reddy's Laboratories Limited in conjunction with their 2025 Q3 earnings call.
Nifty 50 top losers today on January 24: Dr. Reddy’s Laboratories, Trent, and Mahindra & Mahindra and more
The Indian stock market experienced a tough trading session on January 24, with both benchmark indices, Sensex and Nifty, closing in the red. As market sentiment took a hit, the Sensex witnessed a dec...
Dr Reddy's Laboratories CEO: 'very positive outlook' for Indian pharma industry despite Trump 2.0
CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be supported by the Trump administration. A strong U.S. dollar is bolstering e...
Dr Reddy’s shares fall over 5% following Q3 FY25 results
Shares of Dr Reddy’s Laboratories dropped by 5.19% to ₹1,222.50 on Friday, January 24, 2025, following the release of its Q3 FY25 financial results. The decline comes despite the company reporting rec...
Dr Reddy’s Q3 Results: CLSA raises FY25-27 revenue and margin estimates; check target price
CLSA raised revenue and margin estimates slightly for FY25-27, citing higher-than-expected growth in the recently acquired NRT portfolio.
CLSA reiterates Sell call on Dr Reddy’s following Q3 results missing estimates
Citi has reiterated its Sell rating on Dr. Reddy’s Laboratories with a target price of ₹1,100, citing a subdued Q3FY25 performance. Adjusted PAT missed expectations by around 10%, impacted by a pronou...
HSBC maintains Hold call on Dr Reddy’s after Q3FY25 earnings, target at Rs 1,250
HSBC has maintained a Hold rating on Dr. Reddy's Laboratories (DRL) with a target price of ₹1,250.
Hindustan Unilever, Dr Reddy’s Laboratories: Stocks on radar today
India Business News: Axis Securities has downgraded Hindustan Unilever to ‘hold’ rating with a target price of Rs 2,520 (+8%).
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ETCompany ParticipantsRicha Periwal – Head-Investor...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
On Thursday, Dr. Reddy's Laboratories Ltd (NYSE: RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginall...
Dr. Reddy's reports Q3 results
Dr Reddy's Laboratories Ltd (RDY) Reports Strong Financial Performance for Q3FY25
Dr Reddy's Laboratories Ltd (RDY) Reports Strong Financial Performance for Q3FY25
Dr. Reddy's Q3 & 9MFY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
Top Stocks To Watch In Trade Tomorrow, January 24: HPCL, Dr Reddy’s Labs, Cyient, Mankind Pharma, Indus Towers, Kotak Mahindra Bank and more in focus
Several notable stocks are set to be in focus tomorrow, January 24 due to Q3FY25 earnings announcements and key corporate developments.
Dr Reddy's Q3 PAT rises 2% despite 16% jump in revenues
India Business News: HYDERABAD: Despite posting record revenues, pharma major Dr Reddy’s Laboratories on Thursday reported a marginal 2% increase in consolidated profit af.
Dr Reddy's Q3 profit up 2% at Rs 1,413 crore; revenue at Rs 8,359 crore
Dr Reddy's Laboratories saw a 2% rise in consolidated net profit to Rs 1,413 crore in Q3 FY24, driven by strong market performance. Revenue grew to Rs 8,359 crore, with notable growth in the US, India...
Earnings Scheduled For January 23, 2025
Companies Reporting Before The Bell • Elevance Health (NYSE: ELV) is estimated to report quarterly earnings at $3.86 per share on revenue of $44.72 billion. • Chunghwa Telecom (NYSE: CHT) is project...